{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T06:42:34Z","timestamp":1777358554924,"version":"3.51.4"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.radonc.2020.07.014","type":"journal-article","created":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T21:32:19Z","timestamp":1594503139000},"page":"26-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients"],"prefix":"10.1016","volume":"151","author":[{"given":"Rebecca","family":"Levin-Epstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan R.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Karen","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard G.","family":"Stock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Jeffrey Demanes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean P.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8078-0438","authenticated-orcid":false,"given":"Nima","family":"Aghdam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simeng","family":"Suy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantine","family":"Mantz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan J.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas G.","family":"Nickols","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leszek","family":"Miszczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Napieralska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Namysl-Kaletka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas D.","family":"Prionas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5888-4684","authenticated-orcid":false,"given":"Hilary","family":"Bagshaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark K.","family":"Buyyounouski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minsong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon A.","family":"Mahal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0817-2697","authenticated-orcid":false,"given":"David","family":"Shabsovich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Dang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8339-0504","authenticated-orcid":false,"given":"Ye","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew B.","family":"Rettig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4916-5047","authenticated-orcid":false,"given":"Albert J.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William C.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel E.","family":"Spratt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1216-6230","authenticated-orcid":false,"given":"Eric J.","family":"Lehrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4932-1986","authenticated-orcid":false,"given":"Nicholas G.","family":"Zaorsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick A.","family":"Kupelian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael L.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric M.","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi Y.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amar U.","family":"Kishan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2020.07.014_b0005","unstructured":"Mohler JL, Hurwitz M, Richey S. Prostate Cancer version 1.2020. NCCN Guidelines. Published online 2020."},{"key":"10.1016\/j.radonc.2020.07.014_b0010","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.urology.2008.07.064","article-title":"Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer","volume":"73","author":"Morris","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.radonc.2020.07.014_b0015","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.brachy.2016.11.002","article-title":"High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer","volume":"16","author":"Patel","year":"2017","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2020.07.014_b0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.8006","article-title":"Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer","volume":"2","author":"Kishan","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.radonc.2020.07.014_b0025","doi-asserted-by":"crossref","unstructured":"Lazarev S, Thompson MR, Stone NN, Stock RG. Low-dose-rate brachytherapy for prostate cancer: outcomes at >10 years of follow-up. BJU Int 2018;121:781\u2013790. doi:10.1111\/bju.14122","DOI":"10.1111\/bju.14122"},{"key":"10.1016\/j.radonc.2020.07.014_b0030","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.eururo.2011.08.029","article-title":"Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes","volume":"60","author":"Zelefsky","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2020.07.014_b0035","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.ijrobp.2005.07.006","article-title":"PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis","volume":"64","author":"Ray","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.07.014_b0040","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.urology.2006.08.1056","article-title":"Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure","volume":"68","author":"Ray","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.radonc.2020.07.014_b0045","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0090-4295(99)00346-5","article-title":"Post-treatment PSA \u22640.2\u00a0ng\/ml defines disease freedom after radiotherapy for prostate cancer using modern techniques","volume":"54","author":"Critz","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.radonc.2020.07.014_b0050","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ijrobp.2013.10.010","article-title":"Prostate-specific antigen at 4 to 5 years after low-dose-rate prostate brachytherapy is a strong predictor of disease-free survival","volume":"88","author":"Lo","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.07.014_b0055","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.radonc.2018.03.005","article-title":"Dose escalation for prostate stereotactic ablative radiotherapy (SABR): late outcomes from two prospective clinical trials","volume":"127","author":"Alayed","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.07.014_b0060","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12894-019-0493-1","article-title":"Prostate-specific antigen (PSA) and distress: \u2013 a cross-sectional nationwide survey in men with prostate cancer in Sweden","volume":"19","author":"R\u00f6nning\u00e5s","year":"2019","journal-title":"BMC Urol"},{"key":"10.1016\/j.radonc.2020.07.014_b0065","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3109\/0284186X.2016.1150607","article-title":"Fear of cancer recurrence in prostate cancer survivors","volume":"55","author":"van de Wal","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2020.07.014_b0070","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.07.014_b0075","doi-asserted-by":"crossref","unstructured":"Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis. 2nd ed.; 2011. doi:10.1002\/9781119513469","DOI":"10.1002\/9781119513469"},{"key":"10.1016\/j.radonc.2020.07.014_b0080","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1177\/0962280212445839","article-title":"Joint latent class models for longitudinal and time-to-event data: a review","volume":"23","author":"Proust-Lima","year":"2014","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.radonc.2020.07.014_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v078.i02","article-title":"Estimation of extended mixed models using latent classes and latent processes: The R Package lcmm","volume":"78","author":"Proust-Lima","year":"2017","journal-title":"J Stat Softw"},{"key":"10.1016\/j.radonc.2020.07.014_b0090","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1259\/0007-1285-62-735-241","article-title":"Radiobiological assessment of permanent implants using tumour repopulation factors in the linear-quadratic model","volume":"62","author":"Dale","year":"1989","journal-title":"Br J Radiol"},{"key":"10.1016\/j.radonc.2020.07.014_b0095","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0360-3016(01)01601-7","article-title":"10-year biochemical (prostate-specific antigen) control of prostate cancer with 125I brachytherapy","volume":"51","author":"Grimm","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.07.014_b0100","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.clon.2016.10.001","article-title":"Stereotactic ablative radiotherapy versus low dose rate brachytherapy or external beam radiotherapy: propensity score matched analyses of Canadian data","volume":"29","author":"Loblaw","year":"2017","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2020.07.014_b0105","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.prro.2015.11.002","article-title":"SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer","volume":"6","author":"Kishan","year":"2016","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2020.07.014_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/jcb.2018.73786","article-title":"Time to PSA rise differentiates the PSA bounce after HDR and LDR brachytherapy of prostate cancer","volume":"10","author":"Burchardt","year":"2018","journal-title":"J Contemp Brachytherapy"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814020304072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814020304072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:10:44Z","timestamp":1759122644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814020304072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":22,"alternative-id":["S0167814020304072"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2020.07.014","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2020.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}